With the pandemic easing, the federal agency’s long-term agenda for drug approvals or new issues is languishing without a permanent commissioner.
Published: June 12, 2021 at 04:34PM
from NYT Health https://ift.tt/3pMFTqr
With the pandemic easing, the federal agency’s long-term agenda for drug approvals or new issues is languishing without a permanent commissioner.
Published: June 12, 2021 at 04:34PM
from NYT Health https://ift.tt/3pMFTqr